United States News Todas as matérias

Keurig Dr Pepper (NASDAQ:KDP) disclosed executive changes as it advances plans to separate its beverage and coffee businesses into two standalone companies in early 2027.

AbbVie (NYSE:ABBV) secured European Commission approval for SKYRIZI to treat pediatric plaque psoriasis patients aged six and older.

Technology stocks came under heavy selling pressure with Nasdaq 100 futures pointing to a 2.8% decline and S&P 500 futures down 1.4%.

Arrowhead Pharmaceuticals (NASDAQ:ARWR) announced today that the European Commission has granted marketing authorization for REDEMPLO (plozasiran) as an adjunct to diet for treating adults with familial chylomicronemia syndrome (FCS).

HII (NYSE:HII) announced today that its Mission Technologies division has received a $418 million, five-year indefinite delivery/indefinite quantity (IDIQ) contract to support U.S. Navy fleet operational readiness.

Eli Lilly (NYSE:LLY) announced that its board of directors has declared a cash dividend of $1.73 per share on outstanding common stock for the third quarter of 2026.

SpaceX (NASDAQ:SPCX) has initiated its first-ever bond sale to repay outstanding debt following a 7% decline in its share price during early Monday trade.

INVO Fertility (NASDAQ:IVF) recorded a 23% increase in year-over-year revenue to $2.02 million for the first quarter of 2026.

NRx Pharmaceuticals (NASDAQ:NRXP) secured FDA authorization for a depression treatment protocol with an initial drug cost of $0.

TScan Therapeutics (NASDAQ:TCRX) reported initial clinical trial data showing 11 out of 14 blood cancer patients achieved complete donor chimerism.

Eledon Pharmaceuticals (NASDAQ:ELDN) reported extension data showing a 12 mL/min kidney function advantage at 18 months.

Clinical-stage biopharmaceutical firm Traws Pharma (NASDAQ:TRAW) updated guidance for its influenza prophylaxis program to enable a planned Phase 2a trial.

Workforce solutions provider Atlantic International (NASDAQ:ATLN) reported first-quarter 2026 revenue of $249.9 million.

Biopharmaceutical firm Nuvectis (NASDAQ:NVCT) licensed exclusive ex-China rights for two clinical drug assets in a deal valued up to $1.461 billion.

Biotechnology firm bioAffinity Technologies (NASDAQ:BIAF) announced preclinical findings showing its novel small interfering RNA therapeutic approach selectively destroys cells from two common skin cancers that affect an estimated 5.4 million annual United States cases.

Booz Allen Hamilton (NYSE:BAH) executed a definitive agreement to acquire Ultra I&C Mission Solutions for $720 million to expand its defense technology portfolio.

Worksport (NASDAQ:WKSP) announced a preliminary gross margin of approximately 35% for the month of May 2026.

Outdoor Holding Company (NASDAQ:POWW) reported a 10.1% increase in fourth-quarter revenue to $13.9 million.

Palvella Therapeutics (NASDAQ:PVLA) announced that the FDA granted rolling review for its rare genetic disease drug application.

Organon (NYSE:OGN) finalized a global licensing agreement with Sebela Pharmaceuticals for a hormone-free birth control device that is 99% effective.

REGENXBIO (NASDAQ:RGNX) aligned with the FDA to resubmit its rare disease drug application in Q3 2026.

MapLight (NASDAQ:MPLT) announced that its Phase 2 autism trial of 161 patients missed its primary efficacy endpoint.

CRH (NYSE:CRH) signed a definitive agreement to purchase competitor Arcosa for $150 per share in cash.

Fervo Energy (NASDAQ:FRVO) reported a first-quarter net loss of $31.8 million while funding multiple utility-scale geothermal facilities.